Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lowered its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 75.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 482,481 shares of the company’s stock after selling 1,516,219 shares during the period. Federated Hermes Inc. owned 0.68% of Zentalis Pharmaceuticals worth $1,973,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Eventide Asset Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 47.9% during the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after acquiring an additional 3,745,936 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after purchasing an additional 585,644 shares during the last quarter. Decheng Capital LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at approximately $31,809,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Zentalis Pharmaceuticals by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock worth $6,754,000 after buying an additional 3,759 shares during the last quarter. Finally, Rafferty Asset Management LLC raised its position in shares of Zentalis Pharmaceuticals by 79.4% during the 4th quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock valued at $5,456,000 after buying an additional 159,439 shares during the period.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL opened at $4.22 on Friday. The firm has a market cap of $299.73 million, a price-to-earnings ratio of -1.27 and a beta of 1.70. The firm has a 50 day simple moving average of $3.55 and a 200-day simple moving average of $8.48. Zentalis Pharmaceuticals, Inc. has a one year low of $2.83 and a one year high of $22.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same quarter in the prior year, the firm earned ($1.85) EPS. Equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ZNTL. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $29.00 to $9.00 in a research report on Tuesday, June 18th. UBS Group downgraded Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $28.00 to $5.00 in a research report on Thursday, June 20th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $6.00 price objective (down from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.78.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.